Todays NewsNews confirms pela's effect on cancer but once again the market's reaction thus far is anything but enthusiastic. As has been observed by this board and others the lack of management participation doesn't help the cause. One would think that with the lack of viable teatments for pan cancer the FDA would promote this to an accelerated approval and why haven't they. An accelerated approval would kick start the bidding and show the confidence in the product that isn't being show currently.